United States,Austria,Belgium,Czech Republic,Denmark,Finland,France,Germany,Hungary,Ireland,Italy,Luxembourg,Netherlands,Norway,Poland,Portugal,Romania,Slovak Republic,Spain,Sweden,United Kingdom,Global Site
- Home
- Insights
- Science and the law: Prepare for 2024 with our most popular insights
4 January 2024 • 1 minute read
Science and the law: Prepare for 2024 with our most popular insights
Throughout 2023, DLA Piper’s lawyers have continued providing you with insights on the latest business and legal developments at the intersection of science and the law. Here are 10 of our most popular podcasts, videos, and publications that we think will help guide you into 2024.
The DLA Piper Life Sciences Summit brought together pharmaceutical, biotechnology, and medical device companies from around the world to discuss emerging trends and challenges facing the industry. Download our recap.
A change to the California Evidence Code goes into effect in 2024 that will make it harder for product defendants to admit expert testimony regarding alternative causes of a plaintiff’s injury.
This edition of our AI ChatRoom video series explores emerging issues in artificial intelligence and digital health. Watch it here.
The FDA explains how it is planning to apply its regulations to modern clinical trial designs. “Work smarter, not harder” is key to this approach.
Long-awaited draft guidance from the Center for Devices and Radiological Health aims to modernize and streamline the 510(k) process.
In our At the Intersection of Science and Law podcast, we discuss emerging EU and US perspectives on privacy considerations in cross-border clinical trials. Listen here.
The latest in the gene editing landscape: FDA addresses CRISPR-Cas9 in human therapeutics; an update on CRISPR patent disputes; and here come Fanzors.
Pharmacy benefit managers wield the power to not only increase what consumers pay for their medicines, but whether consumers even have access to those medicines. Is PBM disruption on the horizon?
The FTC says it intends to investigate whether improper patent listings violate the FTC Act - the latest sign that it is monitoring Orange Book listings as part of its antitrust enforcement mission.
The mifepristone litigation has created an array of implications for life sciences companies. Our At the Intersection of Science and Law podcast tells you more.